Due to the complexity of Alzheimer's disease, multiple cellular types need to be targeted simultaneously in order for a given therapy to demonstrate any major effectiveness. Ultrasound-sensitive coated microbubbles (in a targeted lipid nanoemulsion) are available. Versatile small molecule drug(s) targeting multiple pathways of Alzheimer's disease pathogenesis are known. By incorporating such drug(s) into the targeted “lipid-coated microbubble” [LCM]/“nanoparticle-derived” [ND] (or LCM/ND) nanoemulsion type, one obtains a multitasking combination therapeutic for translational medicine. This multitasking therapeutic targets cell-surface scavenger receptors (mainly class B type I), or SR-BI, making possible for various Alzheimer's-related cell types to be simultaneously searched out for localized drug treatment in vivo. Besides targeting cell-surface SR-BI, the proposed LCM/ND-nanoemulsion combination therapeutic(s) include a characteristic lipid-coated microbubble [LCM] subpopulation (i.e., a stable LCM suspension); such film-stabilized microbubbles are well known to substantially reduce the acoustic power levels needed for accomplishing temporary noninvasive (transcranial) ultrasound treatment, or sonoporation, if additionally desired for the Alzheimer's patient.

由于阿尔茨海默氏病的复杂性，需要同时针对多种细胞类型进行靶向治疗，以使给定的治疗方法显示出任何主要疗效。可以使用超声敏感的包被的微泡（在靶向脂质纳米乳剂中）。靶向阿尔茨海默氏病发病机理的多种途径的多功能小分子药物是已知的。通过将这类药物掺入靶向的“脂质包裹的微泡” [LCM] /“纳米颗粒衍生的” [ND]（或LCM / ND）纳米乳剂类型中，可以获得用于转化药物的多任务组合治疗剂。这种多任务治疗剂靶向细胞表面清除剂受体（主要是B类I型）或SR-BI，从而有可能同时搜寻各种与阿尔茨海默氏症相关的细胞类型，以进行体内局部药物治疗。除了靶向细胞表面的SR-BI，拟议的LCM / ND-纳米乳剂联合治疗药物还包括特征性的脂质包裹的微泡[LCM]亚群（即稳定的LCM悬浮液）；众所周知，如果阿尔茨海默氏病患者另外需要的话，这种薄膜稳定的微气泡会大大降低完成临时性非侵入性（经颅）超声治疗或声穿孔所需的声功率水平。